Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Ophthalmology and Therapy
Published in: Ophthalmology and Therapy 1/2016

Open Access 01-06-2016 | Review

The Treatment Paradigm for the Implantable Miniature Telescope

Authors: Vincent S. Hau, Nikolas London, Michelle Dalton

Published in: Ophthalmology and Therapy | Issue 1/2016

Login to get access

Abstract

Advanced or end-stage age-related macular degeneration (AMD) results in significant visual impairment and a substantially reduced quality of life for patients. Therapeutic options for people with bilateral moderate or profound vision loss caused by end-stage AMD are limited. Although medical treatment capable of reversing the functional vision loss that results from end-stage AMD is non-existent, there are now treatments that can reverse some of that functional vision loss, including the implantable miniature telescope (IMT). This review article discusses the science behind the IMT, evaluates the data from clinical studies, and weighs the pros and cons of the technology.
Literature
1.
Singer MA, Amir N, Herro A, et al. Improving quality of life in patients with end-stage age-related macular degeneration: focus on miniature ocular implants. Clin Ophthalmol. 2012;6:33–9.PubMed
2.
3.
Congdon N, O’Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122(4):477–85.CrossRefPubMed
4.
American Academy of Ophthalmology Retina Panel. Preferred practice pattern: age-related macular degeneration. San Francisco: AAO; 2015.
5.
Grunwald JE, Daniel E, Huang J, et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121(1):150–61.CrossRefPubMed
6.
Grunwald JE, Pistilli M, Ying GS, et al. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2015;122(4):809–16.CrossRefPubMed
7.
Thalgott V, Feucht N, Lohmann CP, Maier M. Long-term results in neovascular age-related macular degeneration: changes in visual acuity and geographic atrophy during long-standing anti-VEGF therapy. Ophthalmologe. 2016. doi:10.​1007/​s00347-016-0228-6.
8.
Brown GC, Brown MM, Sharma S, et al. The burden of age-related macular degeneration: a value-based medicine analysis. Trans Am Ophthalmol Soc. 2005;103:173–84 (discussion 84–6).PubMedPubMedCentral
9.
Schmier JK, Halpern MT, Covert D, et al. Impact of visual impairment on use of caregiving by individuals with age-related macular degeneration. Retina. 2006;26(9):1056–62.CrossRefPubMed
10.
11.
Mu Y, Zhao M, Su G. Stem cell-based therapies for age-related macular degeneration: current status and prospects. Int J Clin Exp Med. 2014;7(11):3843–52.PubMedPubMedCentral
12.
Geltzer A, Turalba A, Vedula SS. Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2013;1:CD005022.PubMedPubMedCentral
13.
Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med. 2008;358(24):2606–17.CrossRefPubMed
14.
Fernandez-Robredo P, Sancho A, Johnen S, et al. Current treatment limitations in age-related macular degeneration and future approaches based on cell therapy and tissue engineering. J Ophthalmol. 2014;2014:510285.PubMedPubMedCentral
15.
Schmidt-Erfurth U, Chong V, Loewenstein A, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98(9):1144–67.CrossRefPubMedPubMedCentral
16.
Colenbrander A. Visual standards: aspects and ranges of vision loss with emphasis on population surveys. Sydney: International Council of Ophthalmology; 2002.
17.
18.
Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013;309(19):2005–15.CrossRef
19.
Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the Age-Related Eye Disease Study report number 6. Am J Ophthalmol. 2001;132(5):668–81.CrossRef
20.
Cahill MT, Mruthyunjaya P, Bowes Rickman C, Toth CA. Recurrence of retinal pigment epithelial changes after macular translocation with 360 degrees peripheral retinectomy for geographic atrophy. Arch Ophthalmol. 2005;123(7):935–8.CrossRefPubMed
21.
22.
Forooghian F, Agron E, Clemons TE, et al. Visual acuity outcomes after cataract surgery in patients with age-related macular degeneration: age-related eye disease study report no. 27. Ophthalmology. 2009;116(11):2093–100.CrossRefPubMedPubMedCentral
23.
Hooper P, Jutai JW, Strong G, Russell-Minda E. Age-related macular degeneration and low-vision rehabilitation: a systematic review. Can J Ophthalmol. 2008;43(2):180–7.CrossRefPubMed
24.
25.
Goldstein JE, Chun MW, Fletcher DC, et al. Visual ability of patients seeking outpatient low vision services in the United States. JAMA Ophthalmol. 2014;132(10):1169–77.CrossRefPubMed
26.
Rovner BW, Casten RJ, Hegel MT, et al. Low vision depression prevention trial in age-related macular degeneration: a randomized clinical trial. Ophthalmology. 2014;121(11):2204–11.CrossRefPubMedPubMedCentral
27.
Zebardast N, Swenor BK, van Landingham SW, et al. Comparing the impact of refractive and nonrefractive vision loss on functioning and disability: the salisbury eye evaluation. Ophthalmology. 2015;122(6):1102–10.CrossRefPubMedPubMedCentral
28.
Tremblay E. Smart glasses and telescopic contact lenses for macular degeneration. AAAS 2015 Annual Meeting, San Jose, CA, February 13, 2015.
29.
Goldstein JE, Jackson ML, Fox SM, et al. Clinically meaningful rehabilitation outcomes of low vision patients served by outpatient clinical centers. JAMA Ophthalmol. 2015;133(7):762–9.CrossRefPubMed
30.
Maghami MH, Sodagar AM, Lashay A, et al. Visual prostheses: the enabling technology to give sight to the blind. J Ophthalmic Vis Res. 2014;9(4):494–505.CrossRefPubMedPubMedCentral
31.
Second Sight announces first age-related macular degeneration patient receives the Argus II Retinal Prosthesis System as part of groundbreaking study. Sylmar: Second Sight; 2015.
32.
Hengerer FH, Artal P, Kohnen T, Conrad-Hengerer I. Initial Clinical results of a new telescopic IOL implanted in patients with dry age-related macular degeneration. J Refract Surg. 2015;31(3):158–62.CrossRefPubMed
33.
Orzalesi N, Pierrottet CO, Zenoni S, Savaresi C. The IOL-Vip System: a double intraocular lens implant for visual rehabilitation of patients with macular disease. Ophthalmology. 2007;114(5):860–5.CrossRefPubMed
34.
Hudson HL, Lane SS, Heier JS, et al. Implantable miniature telescope for the treatment of visual acuity loss resulting from end-stage age-related macular degeneration: 1-year results. Ophthalmology. 2006;113(11):1987–2001.CrossRefPubMed
35.
Hudson HL, Stulting RD, Heier JS, et al. Implantable telescope for end-stage age-related macular degeneration: long-term visual acuity and safety outcomes. Am J Ophthalmol. 2008;146(5):664–73.CrossRefPubMed
36.
Boyer D, Freund KB, Regillo C, et al. Long-term (60-month) results for the implantable miniature telescope: efficacy and safety outcomes stratified by age in patients with end-stage age-related macular degeneration. Clin Ophthalmol. 2015;9:1099–107.CrossRefPubMedPubMedCentral
37.
38.
Colby KA, Chang DF, Stulting RD, Lane SS. Surgical placement of an optical prosthetic device for end-stage macular degeneration: the implantable miniature telescope. Arch Ophthalmol. 2007;125(8):1118–21.CrossRefPubMed
39.
Brown GC, Brown MM, Lieske HB, et al. Comparative effectiveness and cost-effectiveness of the implantable miniature telescope. Ophthalmology. 2011;118(9):1834–43.CrossRefPubMed
40.
Chan TL. Implantable miniature telescope. Cataract and refractive surgery today, vol. 26. Bryn Mawr: BMC Publications; 2013.
41.
Joondeph BC. Anti-vascular endothelial growth factor injection technique for recurrent exudative macular degeneration in a telescope-implanted eye. Retin Cases Brief Rep. 2014;8(4):342–4.CrossRefPubMed
42.
Schlimgen M, Fortin MJ, Joondeph B. OCT imaging in eyes with an implanted telescope. Retina today, vol. 10. Bryn Mawr: BMC Publications; 2015.
43.
Bourne WM, Nelson LR, Hodge DO. Continued endothelial cell loss ten years after lens implantation. Ophthalmology. 1994;101(6):1014–22 (discussion 22–3).CrossRefPubMed
44.
Dhasmana R, Singh IP, Nagpal RC. Corneal changes in diabetic patients after manual small incision cataract surgery. J Clin Diagn Res. 2014;8(4):VC03–6.PubMedPubMedCentral
45.
Ing JJ, Ing HH, Nelson LR, et al. Ten-year postoperative results of penetrating keratoplasty. Ophthalmology. 1998;105(10):1855–65.CrossRefPubMed
46.
Metadata
Title
The Treatment Paradigm for the Implantable Miniature Telescope
Authors
Vincent S. Hau
Nikolas London
Michelle Dalton
Publication date
01-06-2016
Publisher
Springer Healthcare
Published in
Ophthalmology and Therapy / Issue 1/2016
Print ISSN: 2193-8245
Electronic ISSN: 2193-6528
DOI
https://doi.org/10.1007/s40123-016-0047-5

Other articles of this Issue 1/2016

Ophthalmology and Therapy 1/2016 Go to the issue

Case Series

Case Series Investigating the Efficacy and Safety of Bilateral Fluocinolone Acetonide (ILUVIEN®) in Patients with Diabetic Macular Edema

Original Research

Elevated Intraocular Pressure After Intravitreal Steroid Injection in Diabetic Macular Edema: Monitoring and Management

Case Report

Nd:YAG Laser Hyaloidotomy for the Treatment of Acute Subhyaloid Hemorrhage: A Comparison of Two Cases

Original Research

Electronic Patient Records to Identify Patients in the United Kingdom with Diabetic Macular Oedema Suitable for ILUVIEN® (Fluocinolone Acetonide)

Original Research

Revision External Dacryocystorhinostomy Results After a Failed Dacryocystorhinostomy Surgery

Case Report

Exudative Polymorphous Vitelliform Retinopathy: Importance of Early Recognition of the Condition in Patients with Metastatic Melanoma

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits